Skip to main content

Prevalent and Incident Use of Generic Name Kinase Inhibitors

    Basic Details
    Date Posted
    Status
    In progress
    Medical Product
    afatinib dimaleate
    axitinib
    bortezomib
    cabozantinib s-malate
    carfilzomib
    ceritinib
    crizotinib
    dabrafenib mesylate
    dasatinib
    erlotinib HCL
    everolimus
    gefitinib
    ibrutinib
    idelalisib
    imatinib mesylate
    lapatinib ditosylate
    nilotinib HCL
    pazopanib HCL
    ponatinib HCL
    regorafenib
    ruxolitinib phosphate
    sorafenib tosylate
    sunitinib malate
    trametinib dimethyl sulfoxide
    vandetanib
    vemurafenib
    Description

    These reports look at the prevalent and incident use of 27 kinase inhibitors in the Mini-Sentinel Distributed Database (MSDD). These results were generated using the Mini-Sentinel Distributed Query Tool. These queries were run against the Dispensing Summary Table and distributed on November 14, 2014 to 14 Data Partners; these reports include information from 14 Data Partners.

    Additional Details
    FDA Center
    CDER
    Time Period
    2001-2014
    Analysis Type
    Summary Table
    Population / Cohort
    All individuals
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)